Truist Financial Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its target price increased by research analysts at Truist Financial from $365.00 to $390.00 in a note issued to investors on Friday, Marketbeat reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Truist Financial’s price target points to a potential upside of 21.94% from the company’s current price.

Several other research analysts have also commented on PODD. Barclays upped their price objective on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a report on Wednesday. Jefferies Financial Group lifted their price target on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday. Wells Fargo & Company increased their target price on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. The Goldman Sachs Group decreased their target price on Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Finally, Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $370.76.

Insulet Price Performance

PODD opened at $319.82 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50. The firm has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39. The stock’s 50 day simple moving average is $325.06 and its 200 day simple moving average is $309.86.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same period in the previous year, the firm earned $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts predict that Insulet will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PODD. Inspire Investing LLC lifted its position in shares of Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after purchasing an additional 3,088 shares during the last quarter. Gradient Investments LLC purchased a new position in Insulet in the 2nd quarter worth about $17,429,000. Goldman Sachs Group Inc. lifted its holdings in Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares in the last quarter. Vident Advisory LLC purchased a new stake in Insulet in the 1st quarter valued at about $216,000. Finally, Mn Services Vermogensbeheer B.V. grew its stake in Insulet by 7.5% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 27,300 shares of the medical instruments supplier’s stock worth $8,577,000 after acquiring an additional 1,900 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.